{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.015","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.073","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.49","value":"-34.1"},{"groupId":"OG001","spread":"46.49","value":"-27.0"},{"groupId":"OG002","spread":"149.00","value":"-57.4"},{"groupId":"OG003","spread":"126.13","value":"-25.5"},{"groupId":"OG004","spread":"63.61","value":"-22.5"}]}],"title":"Week 4 (n=47, 50, 50, 50, 94)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"85.45","value":"-41.2"},{"groupId":"OG001","spread":"45.80","value":"-31.1"},{"groupId":"OG002","spread":"138.02","value":"-67.8"},{"groupId":"OG003","spread":"101.76","value":"-53.8"},{"groupId":"OG004","spread":"67.39","value":"-25.5"}]}],"title":"Week 8 (n=46, 50, 50, 50, 86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.80","value":"-49.5"},{"groupId":"OG001","spread":"47.41","value":"-30.7"},{"groupId":"OG002","spread":"142.04","value":"-75.0"},{"groupId":"OG003","spread":"88.27","value":"-62.7"},{"groupId":"OG004","spread":"91.79","value":"-33.9"}]}],"title":"Week 12 (n=48, 51, 50, 50, 97)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"97"}],"units":"Participants"}],"description":"The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Part A and had morning stiffness evaluated at analysis time points. LOCF was used to impute missing post-baseline values for Week 12 analysis.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 4, 8, 12","title":"Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness","type":"SECONDARY","unitOfMeasure":"minutes"}